Valeant's (VRX) SEC Correspondence Shows Potential Problems With Tax Accounting, Adjusted Earnings Metrics - Wells Fargo

November 30, 2016 3:05 PM EST Send to a Friend
Wells Fargo reiterated an Underperform rating on Valeant Pharmaceuticals (NYSE: VRX) with a price target of $10-$13. Analyst David Maris ...

To continue reading this article and more like it please sign-in or join today (FREE!)

Member Login